Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Depression (June/July) | 2021

View Archived Issues

CME Post-Test - Depression, TCPR, June/July 2021

June 29, 2021

By successfully completing the test you will be awarded a certificate for 2 CME credits. Read More

Note From the Editor-in-Chief

June 29, 2021

Black-and-white ideas don’t fit well in psychiatry, but they sometimes seep into my work nonetheless. There they nestle into some corner of uncertainty, making things a little more comfortable than they ought to be. In this issue, I expunge a few of them, with a little help from our friends. Read More

Disulfiram: An Underused Strategy for Alcohol Use Disorders

June 29, 2021

Stephen Wyatt, DO.

We unravel the myths that keep psychiatrists from using disulfiram (Antabuse) in alcohol use disorders. In the right patient, this medication is very effective and far less dangerous than the alternative: continued drinking. Read More

Psychotherapy and Medication in Recurrent Depression

June 29, 2021

Giovanni Fava, MD

Antidepressants treat depression, but patients need something more to prevent future episodes. Giovanni Fava describes an evidence-based method that blends medication with psychotherapy in two phases: sequential treatment for prevention of depression. Read More

How to Write an Open Note

June 29, 2021

Tony Thrasher, DO, DFAPA.

Medical notes may never be the same again. The Open Notes policy allows patients to read their record without delay, and nearly prevents doctors from withholding notes in the interest of safety. Here we share tips on how to use this policy to enhance the therapeutic relationship. Read More

Genetic Testing: What You Need to Know in 2021

June 29, 2021

John Nurnberger, MD, PhD

Is genetic testing ready for clinical practice? It depends on which test we’re talking about. In this interview John Nurnberger details the tests to pay attention to on a genetic panel and describes how to use whole exome sequencing (WES) to identify genetic causes of autism and intellectual disability. Read More

Two Negative Studies of Mirtazapine and Riluzole for PTSD in Veterans

June 29, 2021

Richard Moldawsky, MD.

Medications don’t have a good track record in PTSD, particularly in combat related trauma. Here we review two controlled trials where an old standby (mirtazapine) and a hopeful contender (riluzole) come up short. Read More